C. difficile treatment completes second phase of trials

A treatment discovered at the University of Strathclyde for the Clostridium difficile Infection (CDI) has successfully completed the second phase of clinical trials in the US and Canada. The study, by Glasgow-based biopharmaceutical company MGB Biopharma, of the antibacterial treatment, MGB-BP-3, has met its targets of safety, efficacy, and dose…

Blast count prognostic for CML presenting in advanced phase

(HealthDay)—Blast count seems to be the main prognostic count for patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in the American Journal of Hematology. Michael Lauseker, Ph.D., from Ludwig-Maximilians-Universität München in Germany, and colleagues examined prognostic factors for a…